Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Filament Health has completed a further international delivery of its patented, naturally derived psilocybin drug candidate PEX010 to Germany, supporting the first compassionate use program for psilocybin in the European Union The Company believes the continued delivery demonstrates Filament's ability to manufacture, release and supply pharmaceutical-grade botanical psilocybin across international regulatory jurisdictions as new legal access pathways emerge Rhelion intends to leverage Filament's existing GMP manufacturing infrastructure, regulatory experience, intellectual property and international supply capabilities to pursue future commercial supply opportunities as regulated psilocybin markets and patient-access programs develop globally Toronto, Ontario--(Newsfile Corp. - September 3, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector, is pleased to announce that its wholly owned subsidiary, Filament Health Corp. ("Filament"), has completed a further delivery of PEX010, its patented, standardized, GMP-manufactured botanical psilocybin drug candidate, to the Central Institute of Mental Health ("CIMH") in Mannheim, Germany. Germany's compassionate use program for psilocybin in treatment-resistant depression is the first program of its kind in the European Union and represents an important precedent for regulated patient access to psilocybin outside of clinical trials.

Toronto, Ontario--(Newsfile Corp. - August 31, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector, is pleased to report its financial and operational results for the three months ended June 30, 2026 ("Q1 2027"), capping a transitional quarter which culminated in the acquisition of Filament Health Corp. ("Filament"). All figures are reported in Canadian dollars.

A new United States patent, "Dephosphorylation-Controlled Extraction of Phosphorylatable Psychoactive Alkaloids," issued this month, adding to the intellectual property estate behind PEX010, the standardized natural psilocybin drug candidate supporting more than 80 studies worldwide. Toronto, Ontario--(Newsfile Corp. - August 27, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic sector.

Filament Health's patented, naturally derived psilocybin drug candidate PEX010 will be supplied to an investigator initiated Phase 2a study evaluating a group retreat model of psilocybin therapy in people living with metastatic solid tumors or incurable hematologic malignancies. Toronto, Ontario--(Newsfile Corp. - August 25, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic sector.

Collaboration looks to explore the use of Darmiyan's FDA De Novo authorized BrainSee® imaging platform, authorized for predicting risk of progression to Alzheimer's disease in patients with amnestic mild cognitive impairment, as well as Darmiyan's core technology, the Virtual Microscope, tailored towards use in pharmaceutical clinical trials The goal of the collaboration is to inform the identification, selection and monitoring of the best candidates for clinical trials of PEX010, Rhelion's patented, naturally derived psilocybin drug candidate Toronto, Ontario--(Newsfile Corp. - August 20, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector, is pleased to announce that its wholly owned subsidiary, Filament Health Corp. ("Filament"), has entered into a non-binding letter of intent (the "LOI") with Darmiyan, Inc. ("Darmiyan"), a San Francisco based brain technology company, to explore a collaboration combining Darmiyan's artificial intelligence brain imaging platform with PEX010, Filament's patented, standardized, GMP manufactured natural psilocybin drug candidate. Darmiyan is the developer of BrainSee, which in January 2024 received marketing authorization from the U.S. Food and Drug Administration ("FDA") through the De Novo pathway, following the granting of FDA Breakthrough Device Designation in 2021.

Toronto, Ontario--(Newsfile Corp. - August 19, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector, is pleased to announce the appointment of Samiuddin Khaja as Chief Financial Officer ("CFO") effective immediately. The appointment comes as Rhelion continues its evolution into a focused, research-led life sciences company following the acquisition of Filament Health Corp. and the launch of the Rhelion Life Sciences corporate identity.

Filament Health's patented, naturally derived psilocybin drug candidate PEX010 will be supplied to PSI-PARK, an investigator initiated randomized clinical trial evaluating psilocybin for the treatment of depression in Parkinson's disease. Toronto, Ontario--(Newsfile Corp. - August 14, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic sector.